The human monoclonal antibody MOR103, which targets granulocyte-macrophage colony-stimulating factor, was well tolerated and exhibited a satisfactory safety profile in the first human study assessing...

Field of Interest: Rheumatology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.